ConductScience.org, home

Paper29381964

Treatment of aggressive prolactinoma with temozolomide: A case report and review of literature up to date.

Chen C and 6 others. Medicine (Baltimore), 2017. Cited by 18 papers, by iCite.

Cite this record

ConductScience Library. Treatment of aggressive prolactinoma with temozolomide: A case report and review of literature up to date. Papers, record 29381964. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/29381964

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Treatment of aggressive prolactinoma with temozolomide: A case report and review of literature up to date.
PubMed
Journal
Medicine (Baltimore)
PubMed
Year
2017
PubMed
Publication types
Case Reports, Journal Article
PubMed
Citations, by iCite
18
iCite
Relative citation ratio, by iCite
1.01
iCite
Revised in PubMed
2022-10-05
PubMed

Authors7

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Chen CCheng
2Yin SSenlin
3Zhang SShizhen
4Wang MMengmeng
5Hu YYu
6Zhou PPeizhi
7Jiang SShu

Source PubMed

Download CSV of authors

Topics10

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antineoplastic Agents, AlkylatingMajor topic
DacarbazineMajor topic
Pituitary NeoplasmsMajor topic
ProlactinomaMajor topic
Adolescent
Humans
Male
Prolactin
Salvage Therapy
Temozolomide

Source PubMed

Download CSV of topics

References41

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
122404748Pituitary carcinomas and aggressive pituitary tumours: merits and pitfalls of temozolomide treatment.Clin Endocrinol (Oxf)2012https://conductscience.org/library/papers/22404748PubMed
214762579Measurement of Ki-67 antigen in 159 pituitary adenomas using the MIB-1 monoclonal antibody.Braz J Med Biol Res2004https://conductscience.org/library/papers/14762579PubMed
310022862Regulation of p53 function and stability by phosphorylation.Mol Cell Biol1999https://conductscience.org/library/papers/10022862PubMed
424821329Aggressive pituitary adenomas--diagnosis and emerging treatments.Nat Rev Endocrinol2014https://conductscience.org/library/papers/24821329PubMed
516328518The new WHO classification of pituitary tumors: highlights and areas of controversy.Acta Neuropathol2006https://conductscience.org/library/papers/16328518PubMed
622419713Expression of Ki-67, PTTG1, FGFR4, and SSTR 2, 3, and 5 in nonfunctioning pituitary adenomas: a high throughput TMA, immunohistochemical study.J Clin Endocrinol Metab2012https://conductscience.org/library/papers/22419713PubMed
719654234Temozolomide treatment of a pituitary carcinoma and two pituitary macroadenomas resistant to conventional therapy.Eur J Endocrinol2009https://conductscience.org/library/papers/19654234PubMed
821745538O(6)-Methylguanine-DNA methyltransferase (MGMT) in normal tissues and tumors: enzyme activity, promoter methylation and immunohistochemistry.Biochim Biophys Acta2011https://conductscience.org/library/papers/21745538PubMed
921918831Anti-VEGF therapy in pituitary carcinoma.Pituitary2012https://conductscience.org/library/papers/21918831PubMed
1015741248Clinical review: Diagnosis and management of pituitary carcinomas.J Clin Endocrinol Metab2005https://conductscience.org/library/papers/15741248PubMed
1127916892Molecular Mechanisms of p53 Deregulation in Cancer: An Overview in Multiple Myeloma.Int J Mol Sci2016https://conductscience.org/library/papers/27916892PubMed
1220496311SOM230 (pasireotide) and temozolomide achieve sustained control of tumour progression and ACTH secretion in pituitary carcinoma with widespread metastases.Exp Clin Endocrinol Diabetes2010https://conductscience.org/library/papers/20496311PubMed
1320469984Temozolomide-induced inhibition of pituitary adenoma cells.J Neurosurg2011https://conductscience.org/library/papers/20469984PubMed
148692397p53 expression in pituitary adenomas and carcinomas: correlation with invasiveness and tumor growth fractions.Neurosurgery1996https://conductscience.org/library/papers/8692397PubMed
1522818211Temozolomide and unusual indications: review of literature.Cancer Treat Rev2013https://conductscience.org/library/papers/22818211PubMed
1626614517Temozolomide therapy in patients with aggressive pituitary adenomas or carcinomas.J Neurooncol2016https://conductscience.org/library/papers/26614517PubMed
1721715538Pituitary carcinoma with malignant growth from first presentation and fulminant clinical course--case report and review of the literature.J Clin Endocrinol Metab2011https://conductscience.org/library/papers/21715538PubMed
1826106414Temozolomide Therapy for Aggressive Pituitary Tumors: Results in a Small Series of Patients from Argentina.Int J Endocrinol2015https://conductscience.org/library/papers/26106414PubMed
1923365123
DNA mismatch repair protein (MSH6) correlated with the responses of atypical pituitary adenomas and pituitary carcinomas to temozolomide: the national cooperative study by the Japan Society for Hypothalamic and Pituitary Tumors.
J Clin Endocrinol Metab2013https://conductscience.org/library/papers/23365123PubMed
2019846904p53-Mediated down-regulation of the human DNA repair gene O6-methylguanine-DNA methyltransferase (MGMT) via interaction with Sp1 transcription factor.Anticancer Res2009https://conductscience.org/library/papers/19846904PubMed

See all 41 referencesDownload CSV of references

Cited by13

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 18 citations.

PMIDTitleJournalYearIn PapersSource
41793533Aggressive and malignant pituitary tumours: does the sex matter?Pituitary2026https://conductscience.org/library/papers/41793533PubMed
40626090Prolactinoma Resection in a Transgender Woman on Gender-affirming Hormone Therapy.JCEM Case Rep2025https://conductscience.org/library/papers/40626090PubMed
40457103Effect of antineoplastic drug therapies on carcinoma and aggressive pituitary tumors: a systematic review and meta-analysis.Pituitary2025https://conductscience.org/library/papers/40457103PubMed
38370355Prolactin-secreting pituitary adenomas: male-specific differences in pathogenesis, clinical presentation and treatment.Front Endocrinol (Lausanne)2024https://conductscience.org/library/papers/38370355PubMed
37529607Therapeutic response to pazopanib: case report and literature review on molecular abnormalities of aggressive prolactinomas.Front Endocrinol (Lausanne)2023https://conductscience.org/library/papers/37529607PubMed
35865778Aggressive prolactinomas responsive to temozolomide treatment: Report of two cases.Clin Case Rep2022https://conductscience.org/library/papers/35865778PubMed
35059545Temozolomide Nonresponsiveness in Aggressive Prolactinomas and Carcinomas: Management and Outcomes.J Endocr Soc2022https://conductscience.org/library/papers/35059545PubMed
34975752Early Initiation of Temozolomide Therapy May Improve Response in Aggressive Pituitary Adenomas.Front Endocrinol (Lausanne)2021https://conductscience.org/library/papers/34975752PubMed
34934445Aggressive prolactinoma (Review).Exp Ther Med2022https://conductscience.org/library/papers/34934445PubMed
34268462Giant Prolactinoma Presenting With Facial Nerve Palsy and Hemiparesis.J Endocr Soc2021https://conductscience.org/library/papers/34268462PubMed
34195524Long-Term Use of Temozolomide as Safe and Effective Therapy for an Aggressive Corticotroph Adenoma in a Very Old Patient.J Endocr Soc2021https://conductscience.org/library/papers/34195524PubMed
32232709Long-course temozolomide in aggressive pituitary adenoma: real-life experience in two tertiary care centers and review of the literature.Pituitary2020https://conductscience.org/library/papers/32232709PubMed
31522358Dopamine agonist resistant prolactinomas: any alternative medical treatment?Pituitary2020https://conductscience.org/library/papers/31522358PubMed

Download CSV of cited by

Genes7

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/29381964

GET https://conductscience.org/api/papers/v1/29381964/references?page=2